Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD) earnings
Quarterly and annual GLMD reports and results, each read against the price at its own news timestamp. Back to the GLMD overview →
6 measured GLMD earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 | Press release | +0.00% | +0.97% | |
| Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +3.64% | +14.05% | |
| Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | -2.13% | |
| Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -1.45% | +2.17% | |
| Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 | Press release | -1.33% | -2.67% | |
| Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 | Press release | +0.00% | +5.33% |
Keep exploring
More GLMD: analyst actions → · SEC filings → · GLMD overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) | 159 | -1.17% | 27% |
| DURECT Corporation (DRRX) | 159 | +0.03% | 51% |
| GT Biopharma, Inc. (GTBP) | 159 | -0.91% | 32% |
| ImmuCell Corporation (ICCC) | 159 | 0.00% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.